Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis

Autor: Paola Muti, Gregory R. Steinberg, Bruce E. Kemp, Andrew J. O'Brien, Vanessa P. Houde, Linda Villani, Theodoros Tsakiridis, Giovanni Blandino, Sandra Galic, Lindsay A. Broadfield
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Male
Lung Neoplasms
Sodium Salicylate
AMP-Activated Protein Kinases
Biochemistry
chemistry.chemical_compound
Mice
AMP-activated protein kinase
Mice
Knockout

Aspirin
biology
Anti-Inflammatory Agents
Non-Steroidal

mammalian target of rapamycin (mTOR)
Drug Synergism
Metformin
Neoplasm Proteins
Lipogenesis
Female
medicine.drug
acetyl-CoA carboxylase (ACC)
medicine.medical_specialty
Cell Survival
aspirin
proliferation
fatty acids
Internal medicine
Cell Line
Tumor

medicine
Animals
Humans
Hypoglycemic Agents
Protein kinase A
Molecular Biology
Sodium salicylate
Fatty acid synthesis
Binding Sites
AMPK
Prostatic Neoplasms
cholesterol
Cell Biology
Fibroblasts
Embryo
Mammalian

Enzyme Activation
Endocrinology
chemistry
biology.protein
Cancer research
3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase
Acetyl-CoA Carboxylase
Popis: Aspirin, the pro-drug of salicylate, is associated with reduced incidence of death from cancers of the colon, lung and prostate and is commonly prescribed in combination with metformin in individuals with type 2 diabetes. Salicylate activates the AMP-activated protein kinase (AMPK) by binding at the A-769662 drug binding site on the AMPK β1-subunit, a mechanism that is distinct from metformin which disrupts the adenylate charge of the cell. A hallmark of many cancers is high rates of fatty acid synthesis and AMPK inhibits this pathway through phosphorylation of acetyl-CoA carboxylase (ACC). It is currently unknown whether targeting the AMPK–ACC-lipogenic pathway using salicylate and/or metformin may be effective for inhibiting cancer cell survival. Salicylate suppresses clonogenic survival of prostate and lung cancer cells at therapeutic concentrations achievable following the ingestion of aspirin (
Databáze: OpenAIRE